Search Results - Esther Heijnen

Immunogenicity, safety and reactogenicity of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 to 75 years: A comparison of phase 2b and phase 3 clinical trial material by Archana Jastorff, Arangassery Rosemary Bastian, Nynke Ligtenberg, Vladislav Klyashtornyy, Benoît Callendret, Esther Heijnen

Connect to this object online.

MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial... by Aurelio Cruz-Valdez, Gabriel Valdez-Zapata, Sanjay S. Patel, Flavia V. Castelli, Marcia G. Garcia, Wim T. Jansen, Ashwani Kumar Arora, Esther Heijnen

Connect to this object online.

Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life by Tessa Hosman, Roy van Heesbeen, Arangassery Rosemary Bastian, Weihong Hu, Christy Comeaux, Nynke Ligtenberg, Bart van Montfort, Benoît Callendret, Esther Heijnen

Connect to this object online.

Evaluation of symptoms in respiratory syncytial virus infection in adults: psychometric evaluation of the Respiratory Infection Intensity and Impact Questionnaire™ symptom scores by Richard H. Osborne, Lauren M. Nelson, Sheri Fehnel, Nicole Williams, Randall H. Bender, Ryan Ziemiecki, Efi Gymnopoulou, Els De Paepe, Yannick Vandendijck, Lindsey Norcross, Esther Heijnen, Gabriela Ispas, Christy Comeaux, Benoit Callendret, Eric K. H. Chan, Jane A. Scott

Connect to this object online.